Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older

Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children and adolescents five years of age and older, who have not received treatment and who have tested positive for the virus. Pegasys in combination with the antiviral ribavirin is the foundation of treatment for chronic HCV in adults. The medicine was first approved in the European Union over ten years ago.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news